103 Views
Sunday Poster Session
Category: Obesity
Sindhura Kolli, MD
New York University School of Medicine
New York, NY, United States
Total (N=625) | NAFLD Females (N=525) | NAFLD + PCOS Females (N=21) | NAFLD Males (N=79) | p-value | |
Age | 56.93 ± 14.51 | 60.55 ± 12.41 | 36.33 ± 9.91 | 38.37 ± 8.54 | < 0.001*** |
Gender | N/A | ||||
Female | 546 (87.4%) | 525 (100.0%) | 21 (100.0%) | 0 (0.0%) | |
Male | 79 (12.6%) | 0 (0.0%) | 0 (0.0%) | 79 (100.0%) | |
Race | 0.006 | ||||
Caucasian | 364 (58.2%) | 311 (59.2%) | 9 (42.9%) | 44 (55.7%) | |
Black | 38 (6.1%) | 29 (5.5%) | 4 (19.0%) | 5 (6.3%) | |
Asian | 58 (9.3%) | 51 (9.7%) | 2 (9.5%) | 5 (6.3%) | |
Hispanic | 117 (18.7%) | 101 (19.2%) | 5 (23.8%) | 11 (13.9%) | |
Hawaiian or Pacific Islander | 6 (1.0%) | 5 (1.0%) | 0 (0.0%) | 1 (1.3%) | |
Native American | 4 (0.6%) | 4 (0.8%) | 0 (0.0%) | 0 (0.0%) | |
Other | 18 (2.9%) | 9 (1.7%) | 1 (4.8%) | 8 (10.1%) | |
Unknown | 20 (3.2%) | 15 (2.9%) | 0 (0.0%) | 5 (6.3%) | |
Age of NAFLD Diagnosis | 48.83 ±14.39 | 53.48 ± 12.19 | 31.05 ± 8.86 | 33.49 ± 9.02 | < 0.001*** |
BMI (kg/m2) | 32.77 ± 7.08 | 32.35 ± 6.99 | 38.40 ± 6.74 | 34.67 ± 6.91 | < 0.001*** |
Physical Exam Findings of Cirrhosis | < 0.001*** | ||||
Yes | 56 (9.0%) | 49 (9.3%) | 2 (9.5%) | 5 (6.3%) | |
No | 71 (11.4%) | 0 (0.0%) | 0 (0.0%) | 71 (89.9%) | |
Missing | 498 (79.7%) | 476 (90.7%) | 19 (90.5%) | 3 (3.8%) | |
Platelets | 240.11 ± 81.03 | 237.25 ± 82.15 | 287.05 ± 69.83 | 245.99 ± 72.80 | |
AST | 52.02 ± 50.64 | 51.84 ± 52.78 | 49.49 ± 41.38 | 53.82 ± 37.51 | |
ALT | 65.63 ± 65.80 | 61.16 ± 64.07 | 70.05 ± 68.96 | 92.87 ± 69.99 | < 0.001*** |
AST/ALT Ratio | 0.93 ± 0.50 | 0.97 ± 0.50 | 0.92 ± 0.48 | 0.65 ± 0.35 | < 0.001*** |
Albumin | 4.20 ± 0.56 | 4.15 ± 0.54 | 4.03 ± 0.93 | 4.54 ± 0.42 | < 0.001*** |
HgbA1c | 6.44 ± 1.58 | 6.55 ± 1.62 | 6.06 ± 1.12 | 5.91 ± 1.28 | 0.008** |
US Findings of NAFLD | 0.73 | ||||
Yes | 369 (59.0%) | 296 (56.4%) | 13 (61.9%) | 60 (75.9%) | |
No | 16 (2.6%) | 13 (2.5%) | 0 (0.0%) | 3 (3.8%) | |
Missing | 240 (38.4%) | 216 (41.1%) | 8 (38.1%) | 16 (20.3%) | |
CT Findings of NAFLD | 0.024* | ||||
Yes | 152 (24.3%) | 133 (25.3%) | 6 (28.6%) | 13 (16.5%) | |
No | 17 (2.7%) | 12 (2.3%) | 0 (0.0%) | 5 (6.3%) | |
Missing | 456 (73.0%) | 380 (72.4%) | 15 (71.4%) | 61 (77.2%) | |
MRI Findings of NAFLD | < 0.001*** | ||||
Yes | 155 (24.8%) | 135 (25.7%) | 7 (33.3%) | 13 (16.5%) | |
No | 11 (1.8%) | 6 (1.1%) | 0 (0.0%) | 5 (6.3%) | |
Missing | 459 (73.4%) | 384 (73.1%) | 14 (66.7%) | 61 (77.2%) | |
MRE Stage | < 0.001*** | ||||
F0 | 22 (3.5%) | 20 (3.8%) | 2 (9.5%) | 0 (0.0%) | |
F1 | 9 (1.4%) | 1 (0.2%) | 0 (0.0%) | 8 (10.1%) | |
F2 | 8 (1.3%) | 8 (1.5%) | 0 (0.0%) | 0 (0.0%) | |
F3 | 5 (0.8%) | 2 (0.4%) | 0 (0.0%) | 3 (3.8%) | |
F4 | 6 (1.0%) | 4 (0.8%) | 1 (4.8%) | 1 (1.3%) | |
Missing | 575 (92.0%) | 490 (93.3%) | 18 (85.7%) | 67 (84.8%) | |
Fibroscan CAP Steatosis Score | 302.79 ± 65.30 | 302.96 ± 64.70 | 330.50 ± 56.13 | 296.65 ± 70.57 | 0.64 |
Fibroscan Steatosis Grade | 0.75 | ||||
None | 20 (3.2%) | 15 (2.9%) | 0 (0.0%) | 5 (6.3%) | |
S1 | 9 (1.4%) | 5 (1.0%) | 1 (4.8%) | 3 (3.8%) | |
S2 | 10 (1.6%) | 8 (1.5%) | 0 (0.0%) | 2 (2.5%) | |
S3 | 71 (11.4%) | 52 (9.9%) | 3 (14.3%) | 16 (20.3%) | |
Missing | 515 (82.4%) | 445 (84.8%) | 17 (81.0%) | 53 (67.1%) | |
Fibroscan Fibrosis Score (kPa) | 8.68 ± 7.50 | 9.46 ± 8.53 | 7.22 ± 3.14 | 6.49 ± 2.55 | 0.17 |
Fibrosis Score | 0.86 | ||||
F0 | 55 (8.8%) | 38 (7.2%) | 3 (14.3%) | 14 (17.7%) | |
F1 | 26 (4.2%) | 17 (3.2%) | 1 (4.8%) | 8 (10.1%) | |
F2 | 20 (3.2%) | 13 (2.5%) | 0 (0.0%) | 7 (8.9%) | |
F3 | 26 (4.2%) | 20 (3.8%) | 0 (0.0%) | 6 (7.6%) | |
F4 | 28 (4.5%) | 21 (4.0%) | 1 (4.8%) | 6 (7.6%) | |
Missing | 470 (75.2%) | 416 (79.2%) | 16 (76.2%) | 38 (48.1%) | |
NAFLD Score | -0.72 ± 2.24 | -0.47 ± 2.20 | -1.62 ± 2.35 | -2.17 ± 1.86 | < 0.001*** |